Genetically Engineered Constructs in the Comprehensive Treatment of Patients with Chronic Lower Limb Ischemia

Alexander V. Gavrilenko, Evgeny M. Oleynik

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Date, time and location: 2018.05.25 15:30, Congress Hall, 2F–B

Abstract

Introduction: assessment of clinical efficiency in the application of genetically engineered constructs in complex treatment of patients with chronic lower limb ischemia.

Material and methods: results of clinical use of genetically engineered complexes for angiogenesis stimulation on the basis of a vascular endothelial growth factor- 165 at patients with chronic lower limb ischemia are presented in article. Complex treatment of 120 patients IIB-III stages of lower limb ischemia according to A.V. Pokrovsky-Fontaine classificationwas carried out. All patients were devided for two groups – main and control. Genetically engineered complexes for angiogenesis stimulation were used for patients in control group as an independent method of treatment in complex conservative therapy (20 patients), and as the combined treatment – in combination with revascularization surgery (34 patients). Patients in control group were treated with classic conservative therapy (22 patients) and with revascularization surgery only (30 patients).

Results:Positive dynamic was achieved for all patients in the main group. Indicator of clinical efficiency was the increase in claudication distance (p<0,05), increase of ankle-brachial index, improvement of radio-isotope research indicators of blood supply and perfusion of lower limb muscles (p<0,05).At an assessment of clinical efficiency accurate positive dynamics for the main groups of patients was established. The conducted radio isotope researches of soft fabrics also showed improvement of blood supply and perfusion in shin muscles in all cases.

Conclusion: application of genetically engineered constructs for angiogenesis stimulation on the basis of a vascular endothelial growth factor VEGF165 are improving results of surgical treatment for patients with chronic lower limb ischemia. This drug shows good tolerance and safety.